JP2004536077A5 - - Google Patents

Download PDF

Info

Publication number
JP2004536077A5
JP2004536077A5 JP2003501483A JP2003501483A JP2004536077A5 JP 2004536077 A5 JP2004536077 A5 JP 2004536077A5 JP 2003501483 A JP2003501483 A JP 2003501483A JP 2003501483 A JP2003501483 A JP 2003501483A JP 2004536077 A5 JP2004536077 A5 JP 2004536077A5
Authority
JP
Japan
Prior art keywords
composition according
polypeptide
sequence
sequence seq
similarity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003501483A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004536077A (ja
JP4944360B2 (ja
Filing date
Publication date
Priority claimed from EP01401537A external-priority patent/EP1262187A1/en
Application filed filed Critical
Priority claimed from PCT/EP2002/006924 external-priority patent/WO2002098444A2/en
Publication of JP2004536077A publication Critical patent/JP2004536077A/ja
Publication of JP2004536077A5 publication Critical patent/JP2004536077A5/ja
Application granted granted Critical
Publication of JP4944360B2 publication Critical patent/JP4944360B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003501483A 2001-05-25 2002-05-24 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用 Expired - Fee Related JP4944360B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP01401377.5 2001-05-25
EP01401377 2001-05-25
EP01401537.4 2001-06-14
EP01401537A EP1262187A1 (en) 2001-05-25 2001-06-14 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
EP02290795.0 2002-03-29
EP02290795 2002-03-29
PCT/EP2002/006924 WO2002098444A2 (en) 2001-05-25 2002-05-24 Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2009006614A Division JP5717319B2 (ja) 2001-05-25 2009-01-15 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
JP2011263858A Division JP2012111755A (ja) 2001-05-25 2011-12-01 鉄ホメオスタシスの調節剤としてのヘプシジンの使用

Publications (3)

Publication Number Publication Date
JP2004536077A JP2004536077A (ja) 2004-12-02
JP2004536077A5 true JP2004536077A5 (enExample) 2012-01-26
JP4944360B2 JP4944360B2 (ja) 2012-05-30

Family

ID=27224392

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003501483A Expired - Fee Related JP4944360B2 (ja) 2001-05-25 2002-05-24 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
JP2009006614A Expired - Lifetime JP5717319B2 (ja) 2001-05-25 2009-01-15 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
JP2011263858A Pending JP2012111755A (ja) 2001-05-25 2011-12-01 鉄ホメオスタシスの調節剤としてのヘプシジンの使用
JP2014090333A Expired - Lifetime JP5847231B2 (ja) 2001-05-25 2014-04-24 鉄ホメオスタシスの調節剤としてのヘプシジンの使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2009006614A Expired - Lifetime JP5717319B2 (ja) 2001-05-25 2009-01-15 鉄ホメオスタシスの障害を治療するための医薬品を製造するためのヘプシジンの使用
JP2011263858A Pending JP2012111755A (ja) 2001-05-25 2011-12-01 鉄ホメオスタシスの調節剤としてのヘプシジンの使用
JP2014090333A Expired - Lifetime JP5847231B2 (ja) 2001-05-25 2014-04-24 鉄ホメオスタシスの調節剤としてのヘプシジンの使用

Country Status (12)

Country Link
US (4) US7169758B2 (enExample)
EP (2) EP2186524B1 (enExample)
JP (4) JP4944360B2 (enExample)
CN (2) CN101884780B (enExample)
AT (1) ATE427114T1 (enExample)
AU (1) AU2002321105A1 (enExample)
CA (1) CA2448382C (enExample)
CY (1) CY1120241T1 (enExample)
DE (1) DE60231804D1 (enExample)
ES (2) ES2693050T3 (enExample)
TR (1) TR201806761T4 (enExample)
WO (1) WO2002098444A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002321105A1 (en) 2001-05-25 2002-12-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
RU2359268C2 (ru) 2002-11-19 2009-06-20 ДиАрДжи ИНТЕРНЭШНЛ, ИНК. Способ диагностики заболеваний путем скрининга тканей, крови или жидкостей организма животных или человека на предмет обнаружения нефизиологических уровней гепсидина и его терапевтическое применение
US7411048B2 (en) 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
DE10349124A1 (de) 2003-10-22 2005-05-19 Roche Diagnostics Gmbh Differenzialdiagnostik mit Hepcidin
US20060063208A1 (en) 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
KR100679100B1 (ko) * 2004-10-29 2007-02-06 엘지.필립스 엘시디 주식회사 수평 전계 인가형 액정 표시 패널 및 그 제조방법
EP1858541B1 (en) * 2005-02-16 2012-07-25 The General Hospital Corporation Use of bmp antagonists to regulate hepcidin-mediated iron metabolism and treat iron deficiency
WO2007120883A2 (en) * 2006-04-12 2007-10-25 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hepcidin
WO2008011158A2 (en) * 2006-07-21 2008-01-24 Amgen Inc. Method of detecting and/ or measuring hepcidin in a sample
US20090209478A1 (en) * 2006-09-21 2009-08-20 Tomoko Nakayama Compositions and methods for inhibiting expression of the hamp gene
WO2008047485A1 (en) * 2006-10-17 2008-04-24 Naohisa Tomosugi Method for diagnosis of abnormal iron metabolism using active hepcidin as indicator
MX2009008104A (es) * 2007-02-02 2009-08-07 Amgen Inc Hepcidina, antagonistas de hepcidina y metodos de uso.
US8895002B2 (en) 2007-04-09 2014-11-25 The General Hospital Corporation Hemojuvelin fusion proteins and uses thereof
WO2008146903A1 (ja) * 2007-05-31 2008-12-04 Naohisa Tomosugi 活性型ヘプシジンを指標とした、急性虚血性疾患の診断方法
CN101903044A (zh) 2007-10-02 2010-12-01 国家健康与医学研究院 对人铁调素具有特异性的抗原结合蛋白
EP2201382A4 (en) 2007-10-26 2011-01-26 Univ Utah Res Found IDENTIFICATION OF THE HEPCIDIN BINDING PLACE OF FERROPORTIN
TWI409276B (zh) * 2007-11-02 2013-09-21 Lilly Co Eli 抗－海帕西啶（ｈｅｐｃｉｄｉｎ）抗體及其用途
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
NZ590863A (en) * 2008-08-06 2012-10-26 Lilly Co Eli Anti-hepcidin-25 selective antibodies and uses thereof
US20100068737A1 (en) * 2008-09-16 2010-03-18 University Of Tennessee Research Foundation Enzyme-linked Immunosorbent Assay (ELISA) for Canine Hepcidin
US8318167B2 (en) 2008-11-13 2012-11-27 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation of BMP-6
US8999935B2 (en) * 2009-02-11 2015-04-07 New York University Treatment of osteoporosis in peri- and post-menopausal women with hepcidin
DE102009034150A1 (de) * 2009-07-20 2011-01-27 Fresenius Medical Care Deutschland Gmbh Adsorbens zur Adsorption von Hepcidin
TW201109324A (en) 2009-08-20 2011-03-16 Vifor Int Ag Novel quinoline hepcidine antagonists
AR077958A1 (es) 2009-08-27 2011-10-05 Vifor Int Ag Quinoxalinonas antagonistas de la hepcidina
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
CN102712587A (zh) 2009-09-07 2012-10-03 维福（国际）股份公司 新型乙二胺铁调素拮抗剂
TW201111379A (en) 2009-09-09 2011-04-01 Vifor Int Ag Novel thiazole-and oxazole-hepcidine-antagonists
US20120214803A1 (en) 2011-02-18 2012-08-23 Vifor (International) Ag Novel Sulfonaminoquinoline Hepcidin Antagonists
WO2012177921A2 (en) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc Compositions and methods for inhibiting hepcidin antimicrobial peptide (hamp) or hamp-related gene expression
JP5704543B2 (ja) * 2011-06-29 2015-04-22 株式会社ダナフォーム 生体試料の前処理方法、ｒｎａの検出方法及び前処理キット
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
KR102218494B1 (ko) 2013-03-15 2021-02-19 인트린식 라이프사이언시스, 엘엘씨 항-헵시딘 항체 및 그의 용도
WO2014147246A1 (en) 2013-03-21 2014-09-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
US10098878B2 (en) 2014-10-10 2018-10-16 The Board Of Regents Of The University Of Texas System HIF-2α inhibitors for treating iron overload disorders
KR20180109917A (ko) * 2016-01-08 2018-10-08 라 졸라 파마슈티칼 컴파니 헵시딘의 투여 방법
WO2018165186A1 (en) * 2017-03-07 2018-09-13 Intrinsic Lifesciences Llc Assessment of chronic iron deficiency
US20190315821A1 (en) * 2018-02-23 2019-10-17 La Jolla Pharmaceutical Company Compositions comprising hepcidin and methods of use thereof
US12011489B2 (en) 2022-03-30 2024-06-18 Christopher Key Compositions and methods for treating inflammatory disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766207B1 (fr) * 1997-07-11 2000-12-08 Rhone Poulenc Agrochimie Gene chimere codant pour la drosomycine, vecteur le contenant pour la transformation des cellules vegetales et plantes transformees obtenues resistantes aux maladies
FR2770853B1 (fr) * 1997-11-07 1999-12-31 Rhone Poulenc Agrochimie Gene codant pour la thanatine, vecteur le contenant et plantes transformees obtenues resistantes aux maladies
US20030009013A1 (en) * 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000056879A1 (en) * 1999-03-22 2000-09-28 Universität Zürich TRANSFORMING GROWTH FACTOR (TFG) β SUPERFAMILY ANTAGONISTS
AU2002321105A1 (en) 2001-05-25 2002-12-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
US8017737B2 (en) † 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
RU2359268C2 (ru) † 2002-11-19 2009-06-20 ДиАрДжи ИНТЕРНЭШНЛ, ИНК. Способ диагностики заболеваний путем скрининга тканей, крови или жидкостей организма животных или человека на предмет обнаружения нефизиологических уровней гепсидина и его терапевтическое применение
US7411048B2 (en) * 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
EP1858541B1 (en) * 2005-02-16 2012-07-25 The General Hospital Corporation Use of bmp antagonists to regulate hepcidin-mediated iron metabolism and treat iron deficiency
EP2641608B1 (en) * 2006-09-16 2015-03-04 SOY Labs LLC Pharmaceutical composition comprising lunasin enriched seed extract and soy flour
MX2009008104A (es) † 2007-02-02 2009-08-07 Amgen Inc Hepcidina, antagonistas de hepcidina y metodos de uso.
CN101903044A (zh) * 2007-10-02 2010-12-01 国家健康与医学研究院 对人铁调素具有特异性的抗原结合蛋白
WO2009097461A1 (en) 2008-01-29 2009-08-06 Neoguide Systems Inc. Apparatus and methods for automatically controlling an endoscope
CN102245626A (zh) † 2008-12-05 2011-11-16 加利福尼亚大学董事会 微型铁调素肽及其使用方法
HK1199892A1 (en) 2011-12-09 2015-07-24 The Regents Of The University Of California Modified mini-hepcidin peptides and methods of using thereof
JP2017519810A (ja) 2014-04-07 2017-07-20 ラ ホヤ ファーマシューティカル カンパニーＬａ Ｊｏｌｌａ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏｍｐａｎｙ ヘプシジン模倣ペプチドおよびその使用
AU2015279571A1 (en) 2014-06-27 2017-02-02 Protagonist Therapeutics, Inc. Hepcidin and mini-hepcidin analogues and uses therof

Similar Documents

Publication Publication Date Title
JP2004536077A5 (enExample)
EP1105422B1 (en) Hepatitis c inhibitor peptides
US6767991B1 (en) Hepatitis C inhibitor peptides
JP4452401B2 (ja) Ｃ型肝炎ウイルス阻害ペプチドアナログ
EP1105413B1 (en) Hepatitis c inhibitor tri-peptides
JP2008522617A5 (enExample)
WO1999007733A2 (en) Hepatitis c inhibitor peptides
JP2002528060A5 (enExample)
JP2013543497A5 (enExample)
JP2008502301A (ja) ペプチドの抱合
JP2007535910A5 (enExample)
JP2004531242A5 (enExample)
JP2004521123A5 (enExample)
JP2002522508A5 (enExample)
MXPA04005891A (es) Proteinas envolventes del virus de hepatitis c purificadas para diagnostico y uso terapeutico.
JP2004513079A5 (enExample)
JP2007536910A5 (enExample)
JP2011501675A5 (enExample)
JP2007326781A (ja) 抗ｓａｒｓウイルス剤
JP2011515471A5 (enExample)
JPH06220090A (ja) ポリペプチド
WO2002055548A8 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
CN101883784B (zh) N-端修饰的干扰素-α
JP2005500390A5 (enExample)
CN1766115A (zh) 肿瘤血管导向肽与人干扰素α－2b的融合蛋白的制备方法